The abstract is read at the publisher; the summary is JClub's.
In first-line MDM2-amplified locally advanced/metastatic dedifferentiated liposarcoma, brigimadlin did not meet the progression-free survival endpoint versus doxorubicin (8.4 vs 7.2 months; HR 0.79; P=0.096).
- Why it matters: MDM2-p53 antagonism is a targeted strategy for MDM2-amplified DDLPS, but prior evidence needed confirmation against standard chemotherapy using blinded central PFS assessment.
- What they did: In the randomized Brightline-1 phase II/III trial (NCT05218499), patients received brigimadlin (30 or 45 mg in phase II; 45 mg in phase III) or doxorubicin 75 mg/m2 every 3 weeks, with PFS as the primary endpoint.
- The result: Among 148 brigimadlin and 162 doxorubicin recipients, confirmed objective response rates were 22.3% vs 8.6%, grade ≥3 neutropenia (54; 36.7%) and thrombocytopenia (41; 27.9%) were common with brigimadlin, and TP53 pathway activation occurred without predictive biomarkers.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.